Discussion
The first U.S. participants has been dosed in the global portion of a clinical trial program testing if Skyhawk Therapeutics’ experimental therapy SKY-0515 can slow the progression of Huntington’s disease. The global portion (NCT07378644) of the Phase 2/3 trial program, called FALCON-HD, is enrolling up to 400…